Table 1 Patient Characteristics
Characteristics | 60 mg (n = 12) | 200 mg (n = 12) | 400 mg (n = 12) | Total (n = 36) |
|---|---|---|---|---|
Age, years, median (range) | 48 (31-68) | 47.5 (29-67) | 58.5 (47-65) | 52 (29-68) |
Sex, n (%) | ||||
Male | 7 (58.3) | 5 (41.7) | 5 (41.7) | 17 (47.2) |
Female | 5 (41.7) | 7 (58.3) | 7 (58.3) | 19 (52.8) |
Primary site, n (%) | ||||
Acral | 6 (50.0) | 6 (50.0) | 6 (50.0) | 18 (50.0) |
Mucosal | 1 (8.3) | 4 (33.3) | 5 (41.7) | 10 (27.8) |
Cutaneous | 1 (8.3) | 1 (8.3) | 1 (8.3) | 3 (8.3) |
Unknown | 3 (25.0) | 1 (8.3) | 0 | 4 (11.1) |
Uveal | 1 (8.3) | 0 | 0 | 1 (2.8) |
Stagea, n (%) | ||||
M1a | 4 (33.3) | 5 (41.7) | 3 (25.0) | 12 (33.3) |
M1b | 2 (16.7) | 1 (8.3) | 3 (25.0) | 6 (16.7) |
M1c | 5 (41.7) | 5 (41.7) | 5 (41.7) | 15 (41.7) |
M1d | 1 (8.3) | 1 (8.3) | 1 (8.3) | 3 (8.3) |
Metastatic sites, n (%) | ||||
Lymph nodes | 8 (66.7) | 11 (91.7) | 9 (75.0) | 28 (77.8) |
Lung | 8 (66.7) | 5 (41.7) | 8 (66.7) | 21 (58.3) |
Liver | 4 (33.3) | 4 (33.3) | 4 (33.3) | 12 (33.3) |
Bone | 4 (33.3) | 1 (8.3) | 2 (16.7) | 7 (19.4) |
Subcutaneous tissue | 2 (16.7) | 3 (25.0) | 1 (8.3) | 6 (16.7) |
Others | 8 (66.7) | 6 (50.0) | 2 (16.7) | 16 (44.4) |
BRAF status, n (%) | ||||
Mutated | 1 (8.3) | 1 (8.3) | 1 (8.3) | 3 (8.3) |
Wildtype | 11 (91.7) | 11 (91.7) | 11 (91.7) | 33 (91.7) |
ECOG PS, n (%) | ||||
0 | 0 | 4 (33.3) | 4 (33.3) | 8 (22.2) |
1 | 12 (100.0) | 8 (66.7) | 8 (66.7) | 28 (77.8) |
Prior therapy lines, n (%) | ||||
1 | 2 (16.7) | 4 (33.3) | 6 (50.0) | 12 (33.3) |
≥ 2 | 10 (83.3) | 8 (66.7) | 6 (50.0) | 24 (66.7) |
LDH, n (%) | ||||
Normal | 3 (25.0) | 5 (41.7) | 8 (66.7) | 16 (44.4) |
Elevated | 9 (75.0) | 7 (58.3) | 4 (33.3) | 20 (55.6) |